



**Universitätsklinikum  
Leipzig**

Medizin ist unsere Berufung.

**UCL UNIVERSITÄRES  
KREBSZENTRUM**



# ÜBERSICHT ZU ONKOLOGISCHEN STUDIEN AM UNIVERSITÄTSKLINIKUM LEIPZIG

Stand: Juni 2021

## LIEBE KOLLEGINNEN UND KOLLEGEN,

der Studienflyer gibt Ihnen Übersicht über die aktiven onkologischen Therapiestudien am Universitätsklinikum Leipzig, in denen wir Patienten die bestmögliche Versorgung nach aktuellem Stand der klinischen Forschung anbieten können.

Sie finden die Studien nach Indikationen sortiert. Aus Gründen der Übersichtlichkeit sind nur interventionelle Studien aufgelistet. Bitte nehmen Sie mit der Studienassistentin Kontakt auf, wenn Sie weitere Informationen zu einer Studie erhalten wollen. Sie dürfen sich auch immer an das Studienteam des Universitären Krebszentrums wenden. Wir helfen Ihnen gerne weiter.

Wir freuen uns auf eine ausgezeichnete klinisch-wissenschaftliche Kooperation mit Ihnen und hoffen im Sinne der Patienten, dass unser Leipziger Studienportfolio weiterhin intensiv genutzt wird.

Mit kollegialen Grüßen



Prof. Dr. Florian Lordick  
Direktor des UCCL



Dr. Ivonne Haffner  
Leitung  
klinische Forschung



Dr. Gertraud Stocker  
ärztliche Leitung  
Studienteam

## ADENOKARZINOM MAGEN UND GEJ

Primärtherapie,  
neoadjuvant/perioperativ/  
postoperativ

**VESTIGE** Sophia Schmidt 0341 9712596

Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE)

**EORTC Innovation** Sophia Schmidt 0341 9712596

Integration of Trastuzumab, with or without Pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: the INNOVATION-TRIAL

**RACE** Sophia Schmidt 0341 9712596

Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ)

**CARDIA-Trial** Nicole Kreuser 0341 9712590

Surgery for adenocarcinoma of the gastroesophageal junction (GEJ) type II: Transthoracic esophagectomy vs. transhiatal extended gastrectomy

**ProPec** Nicole Kreuser 0341 9712590

Phase II Pilotstudie zur Verminderung der Peritonealkarzinose-Inzidenz nach kurativer Gastrektomie eines Magenkarzinoms oder Adenokarzinoms des gastroösophagealen Übergangs durch hypertherme intraperitoneale Chemoperfusion

**PREVENT** Nicole Kreuser 0341 9712590

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Type II/III adenocarcinoma

## 1. Linie palliativ lokal fortgeschritten oder metastasiert

**Spotlight** Sophia Schmidt 0341 9712596

A phase 3, global, multi-center, double-blind, randomized, efficacy study of Zolbetuximab (IMAB362) plus mFOLFOX6 compared with placebo plus mFOLFOX6 as first-line treatment of subjects with Claudin (CLDN)18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

**Destiny 03** Sophia Schmidt 0341 9712596

Phase 1/2b multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of Trastuzumab Deruxtecan (DS-8201a) monotherapy and combinations in adult subjects with HER2 overexpressing gastric cancer

**Mahogany** Sophia Schmidt 0341 9712596

Phase 2/3 multicenter, international study in patients with metastatic or locally advanced, treatment-naïve, HER2-positive gastric or gastroesophageal junction cancer

## 2. Linie palliativ, lokal fortgeschritten/metastasiert

**CA018-003  
FRACTION** Sophia Schmidt 0341 9712596

A Phase 2, fast real-time assessment of combination therapies in immuno-oncology study in participants with advanced gastric cancer (FRACTION-gastric cancer)

**Ramiris** Sophia Schmidt 0341 9712596

Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy

**20180290-  
AMG199** Sophia Schmidt 0341 9712596

A global phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the half-life extended bispecific T-cell engager AMG 199 in subjects with MUC17-positive gastric and gastroesophageal junction cancer

20180292-  
AMG910

Sophia Schmidt

0341 9712596

A global phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the half-life extended bispecific T-cell engager AMG 910 in subjects with Claudin 18.2-positive gastric and gastroesophageal junction adenocarcinoma

## PLATTENEPHITELKARZINOM ÖSOPHAGUS

### Primärtherapie

Scyscraper

Sophia Schmidt

0341 9712596

A phase III, randomized, double-blind, placebo-controlled study of Atezolizumab with or without Tiragolumab (anti-TIGIT antibody), in patients with unresectable locally advanced esophageal squamous cell carcinoma

## HEPATOZELLULÄRES KARZINOM (HCC)

### Primärtherapie

IRITACE

Carolin Straube

0341 9712328

Transarterielle Chemoembolization (TACE) mit Irinotecan und Mitomycin C im Vergleich zur TACE mit Doxorubicin bei Patienten mit nicht kurativ behandelbarem hepatozellulärem Karzinom - IRITACE - eine randomisierte multicenter Phase 2 Studie. Eine Studie der „German Alliance for Liver Cancer“ (GALC)

### 1. Linie palliativ, lokal fortgeschritten/metastasiert

CA209-9DW

Madlen Steger

0341 9712474

A randomized, multi-center, Phase 3 study of Nivolumab in combination with Ipilimumab compared to Sorafenib or Lenvatinib as first-line treatment in participants with advanced hepatocellular Carcinoma

### 2. Linie palliativ, lokal fortgeschritten/metastasiert

I4T-MC-JVDE  
(REACH 2)

Katja Hirschmann

0341 9712474

Randomized, double-blind, placebo-controlled, phase 3 study of Ramucirumab and Best Supportive Care (BSC) versus placebo and BSC as second-line treatment in patients with hepatocellular carcinoma and elevated baseline Alpha-Fetoprotein (AFP) following first-line therapy without first Sorafenib

<b>CaboRISE</b>	Carolin Straube	0341 9712474
-----------------	-----------------	--------------

A phase II study evaluating reduced starting dose and dose escalation of Cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis

## KOLOREKTALES KARZINOM

### Primärtherapie

<b>Radianc</b>	Sandra Schuster	0341 9716681
----------------	-----------------	--------------

Radiochemotherapy +/- Durvalumab for locally-advanced anal carcinoma. A multicenter, randomized, phase II trial of the German Anal Cancer Study Group

<b>ACO/ARO/ AIO-18.1</b>	Sandra Schuster	0341 9716681
------------------------------	-----------------	--------------

Preoperative oxaliplatin-based chemoradiotherapy and consolidation chemotherapy versus fluorouracil-based chemoradiotherapy for MRI-defined intermediate and high-risk rectal cancer patients. A randomized phase III trial of the German Rectal Cancer Study Group

<b>ACO/ARO/ AIO-18.2</b>	Sophia Schmidt	0341 9712596
------------------------------	----------------	--------------

Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group

<b>CIRCULATE</b>	Nicole Kreuser	0341 9712590
------------------	----------------	--------------

Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung

### Primärtherapie Lebermetastasen

<b>PARLIM</b>	Yvonne Kurth	0341 9712226
---------------	--------------	--------------

Panitumumab after resection of liver metastases from colorectal cancer in RAS wild-type patients

### 1. Linie palliativ, lokal fortgeschritten/metastasiert

<b>FIRE-4</b>	Sophia Schmidt	0341 9712596
---------------	----------------	--------------

Randomised study of the efficacy of Cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus Cetuximab

<b>MoLiMor</b>	Sophia Schmidt	0341 9712596
----------------	----------------	--------------

Modulation of the FOLFIRI-based standard 1st-line therapy with cetuximab, controlled by monitoring the RAS mutation load by liquid biopsy in RAS-mutated mCRC patients

### 2. Linie palliativ, lokal fortgeschritten/metastasiert

<b>RAMTAS</b>	Yvonne Kurth	0341 9712226
---------------	--------------	--------------

A Phase IIb study with run in safety phase of Ramucirumab in combination with TAS102 vs. TAS102 monotherapy refractory metastatic colorectal cancer patients

### 3. Linie palliativ, lokal fortgeschritten/metastasiert

<b>FIRE-4</b>	Sophia Schmidt	0341 9712596
---------------	----------------	--------------

Randomised study of the efficacy of Cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus Cetuximab

## CHOLANGIOKARZINOM

### 1. Linie palliativ, lokal fortgeschritten/metastasiert

<b>FIGHT II</b>	Yvonne Kurth	0341 9712226
-----------------	--------------	--------------

A Phase 3, open-label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of Pemigatinib versus Gemcitabine plus Cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement (FIGHT-302)

<b>PCIA203/18</b>	Yvonne Kurth	0341 9712226
-------------------	--------------	--------------

A multi-centre, randomised, open-label, phase 2 study to assess the safety, tolerability and efficacy of Fimaporfin-induced photochemical internalisation of Gemcitabine complemented by Gemcitabine/Cisplatin chemotherapy versus Gemcitabine/Cisplatin alone in patients with inoperable cholangiocarcinoma

## LUNGENKARZINOM

### Supportivtherapie

ANAM-17-21	Patricia Berger	0341 9712674
------------	-----------------	--------------

A phase III randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of ANAMORELIN HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC

### 1. Linie palliativ, lokal fortgeschritten/metastasiert

MK-3475-671-06	Patricia Berger	0341 9712674
----------------	-----------------	--------------

A Phase III, randomized, double-blind trial of Platinum doublet Chemotherapy +/- Pembrolizumab as neoadjuvant/ adjuvant therapy for participants with resectable stage II, IIIa, and resectable IIIb NSCLC (Keynote-671)

ABP	Patricia Berger	0341 9712674
-----	-----------------	--------------

APB – Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+NSCLC) patients by deep phenotyping

## PROSTATAKARZINOM

### Primärtherapie

LAP-01	Dr. Holze	0341 9717629
--------	-----------	--------------

Prospektive Studie zum Vergleich der Roboter-assistierten und der konventionellen laparoskopischen/endoskopischen radikalen Prostatektomie

Proly	Dr. Holze	0341 9717629
-------	-----------	--------------

Prospektive Erfassung der Lymphozelenhäufigkeit bei robotisch-assistierten-minimal-invasiven radikalen Prostatektomien unter Bildung eines peritonealen Schwenklappens: eine randomisierte kontrollierte verblindete klinische Multicenter-Studie



## ZERVIXKARZINOM

### Primärtherapie

Juliane Gehrt 0341 9711379

Neue Tumoroperationen auf der Grundlage der ontogenetischen Anatomie für die Behandlung des Zervix- und Vaginalkarzinoms: TMMR, KMMR, EMMR, LEER und tLNE

## VULVAKARZINOM

### Primärtherapie

Juliane Gehrt 0341 9711379

Vulvafeldresektion und anatomische Rekonstruktion: Neues operatives Konzept für die Lokalbehandlung des Vulvakarzinoms

## OVARIALKARZINOM

### Primärtherapie

AGO23/  
DUO-O

Juliane Gehrt 0341 9711379

A phase III randomised, double-blind, placebo-controlled, multicentre study of Durvalumab in combination with chemotherapy and Bevacizumab, followed by maintenance Durvalumab, Bevacizumab and Olaparib in newly diagnosed advanced ovarian cancer patients

### 2. Linie palliativ, lokal fortgeschritten/metastasiert

COMPASS Juliane Gehrt 0341 9711379

Comparison of quality of life between Trabectedin/PLD and standard Platinum-based therapy in patients with Platinum sensitive recurrent ovarian, fallopian tube and peritoneal cancer

## ENDOMETRIUMKARZINOM

### Primärtherapie

Juliane Gehrt 0341 9711379

Prospektive monozentrische Beobachtungsstudie: Peritoneale mesometriale Resektion (PMMR), totale mesometriale Resektion (TMMR+) und therapeutische Lymphonodektomie (tLNE) – neue Tumoroperation auf der Grundlage der ontogenetischen Anatomie zur Behandlung des frühen Endometriumkarzinoms (FIGO-Stadium I und II)

**1+2. Linie palliativ,  
lokal fortgeschritten/metastasiert**

**SIENDO/KCP-  
330-024**

Juliane Gehrt

0341 9711379

A randomized, double-blind, phase 3 trial of maintenance with Selinexor / Placebo after combination chemotherapy for patients with advanced or recurrent endometrial cancer

**MAMMAKARZINOM**

**Primärtherapie**

**ADAPTcycle**

Juliane Gehrt

0341 9711379

Adjuvante, auf dynamische Marker adjustierte, personalisierte Therapie zum Vergleich einer endokrinen Behandlung plus Ribociclib mit Chemotherapie bei Hormonrezeptor-positivem, HER2-Rezeptor negative, mittleres Risiko aufweisendem frühen Brustkrebs

**CHECKMATE  
7FL**

Juliane Gehrt

0341 9711379

Randomisierte, multizentrische, doppelblinde, Placebo-kontrollierte Phase 3-Studie zu Nivolumab vs. Placebo in Kombination mit neoadjuvanter Chemotherapie und adjuvanter endokriner Therapie bei Patienten mit primärem Estrogenrezeptor-positivem, humaner-epidermaler-Wachstumsfaktor-Rezeptor-2-negativem Hochrisiko-Brustkrebs (ER+/HER2-)

**1. Linie palliativ,  
lokal fortgeschritten/metastasiert**

**EPIKB3-  
CBYL719H12301**

Sophia Schmidt

0341 9712596

A phase III, multicenter, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation

**CONTESSA  
TRIO**

Juliane Gehrt

0341 9711379

Eine multizentrische Studie der Phase II zu Tesetaxel plus drei verschiedenen PD-(L)1-Inhibitoren bei Patienten mit dreifach negativem, lokal fortgeschrittenem oder metastasierendem Brustkrebs und einer Monotherapie mit Tesetaxel bei älteren Patienten mit HER2-negativem, lokal fortgeschrittenem oder metastasierendem Brustkrebs

**ZNS-TUMORE****Primärtherapie****EORTC-1709-  
BTG**

Nadja Talhi

0341 9718210

A phase III trial of Marizomib in combination with standard Temozolomide-based radiochemotherapy versus standard Temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma

**DOSIS**

Nadja Talhi

0341 9718210

Dose-intensified image-guided fractionated stereotactic body radiation therapy for painful spinal metastases (DOSIS) versus conventional radiation therapy: a phase II randomised controlled trial

**SNOXA**

Nadja Talhi

0341 9718210

Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptosed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Promoter

**EORTC IADL**

Nadja Talhi

0341 9718210

Development of a questionnaire to measure instrumental activities of daily living (I-ADL) in patients with primary brain tumors and brain metastases: Phase IV international field testing

**2. Linie palliativ,  
lokal fortgeschritten/metastasiert****RAGNAR  
(Solide high  
grade ZNS-  
Tumors)**

Sandra Schuster

0341 9720546

A Phase 2 Study of Erdafitinib in subjects with advanced solid tumors and FGFR gene alteration

## KOPF-HALS-KARZINOM

### Primärtherapie

<b>EORTC 1420</b>	Nadja Talhi	0341 9718210
-------------------	-------------	--------------

Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma

<b>ADRISK</b>	Kathrin Vogel	0341 9725052
---------------	---------------	--------------

Postoperative adjuvant radiochemotherapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within the German interdisciplinary study group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk

<b>NadiHN</b>	Kathrin Vogel	0341 9725052
---------------	---------------	--------------

An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating efficacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over 12 months in patients with advanced resectable HNSCC after surgery

### 1. Linie palliativ, lokal fortgeschritten/metastasiert

<b>EORTC 1206</b>	Kathrin Vogel	0341 9725052
-------------------	---------------	--------------

Eine randomisierte Phase II Studie zur Untersuchung der Wirksamkeit und Sicherheit einer Chemotherapie gegenüber einer Androgendeprivationstherapie bei Patienten mit einem Wiederauftreten und/oder Metastasen eines Speicheldrüsenkrebses, welcher Androgen-Rezeptoren aufweist

<b>KO-TIP-007</b>	Kathrin Vogel	0341 9725052
-------------------	---------------	--------------

A pivotal study of Tipifarnib in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS mutations who have failed at least one prior line of therapy

<b>ISA101b</b>	Kathrin Vogel	0341 9725052
----------------	---------------	--------------

Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie zu Cemiplimab im Vergleich zur Kombination aus Cemiplimab und ISA101b bei der Behandlung von Patienten mit HPV16-positivem Oropharynxkarzinom (OPK)

## 2. Linie palliativ, lokal fortgeschritten/metastasiert

<b>ISA101b</b>	Kathrin Vogel	0341 9725052
----------------	---------------	--------------

Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie zu Cemiplimab im Vergleich zur Kombination aus Cemiplimab und ISA101b bei der Behandlung von Patienten mit HPV16-positivem Oropharynxkarzinom (OPK)

<b>AbbVie M19-894</b>	Kathrin Vogel	0341 9725052
-----------------------	---------------	--------------

A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

<b>INTERLINK-1</b>	Kathrin Vogel	0341 9725052
--------------------	---------------	--------------

Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

## MELANOM

### neoadjuvante Therapie

<b>Pivotal PH-191L2TNF-02/15</b>	Silke Weidauer-Zuniga/ Anja Zeuner	0341 9718750/ 0341 9720015
----------------------------------	---------------------------------------	-------------------------------

A phase III, open-label, randomized, controlled multi-center study of the efficacy of L191L2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients

### adjuvante Therapie

<b>NIVO MELA</b>	Mandy Dathe/ Silke Weidauer-Zuniga	0341 9718380/ 0341 9718750
------------------	---------------------------------------	-------------------------------

A phase III randomized, controlled trial with adjuvant nivolumab treatment and biomarker-based risk stratification in stage II high risk melanoma

## lokal fortgeschritten oder metastasiert

<b>MK-7902-003</b>	Mandy Dathe/ Silke Weidauer- Zuniga	0341 9718380/ 0341 9718750
--------------------	---	-------------------------------

A phase 3 randomized, placebo-controlled trial to evaluate the safety and efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) versus Pembrolizumab alone as first-line intervention in participants with advanced melanoma

<b>CA045-001</b>	Silke Weidauer-Zuniga/ Anja Zeuner	0341 9718750/ 0341 9720015
------------------	--	-------------------------------

A phase 3, randomized, open-label study of NKTR-214 combined with Nivolumab versus Nivolumab as first-line intervention in participants with advanced melanoma

<b>V937-011</b>	Mandy Dathe/ Silke Weidauer- Zuniga	0341 9718380/ 0341 9718750
-----------------	---	-------------------------------

A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma

## MERKELZELL-KARZINOM

### lokal fortgeschritten oder metastasiert

<b>Merklin2</b>	Anja Zeuner/ Silke Weidauer- Zuniga	0341 9720015/ 0341 9718750
-----------------	---	-------------------------------

A phase II, open label study to investigate the efficacy and safety of Domatinostat in combination with Avelumab in patients with advanced unresectable/metastatic merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy

## PLATTENEPIHELZELLKARZINOM DER HAUT

### lokal fortgeschritten oder metastasiert

<b>AliCe</b>	Silke Weidauer- Zuniga/ Mandy Dathe	0341 9718750/ 0341 9718380
--------------	---	-------------------------------

Einarmlige, offene, multizentrische Phase II Studie zur Untersuchung der klinischen Aktivität und Sicherheit von Avelumab in Kombination mit Cetuximab bei Studienteilnehmern mit nicht resezierbarem Stadium III oder IV Plattenepithelkarzinom der Haut

<b>Cerpass</b>	Anja Zeuner/ Silke Weidauer- Zuniga	0341 9720015/ 0341 9718750
----------------	---	-------------------------------

A randomized, controlled, open-label, phase 2 study of Cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma

## SARKOM

<b>rEECur</b>	Sophia Schmidt	0341 9712596
---------------	----------------	--------------

International randomised controlled trial for the treatment of recurrent and primary refractory ewing sarcoma

## SOLIDE TUMORE

### ab 1. Linie palliativ, lokal fortgeschritten/metastasiert

<b>RAGNAR</b>	Nadja Talhi/ Sophia Schmidt	0341 9718210/ 03419712596
---------------	--------------------------------	------------------------------

A phase 2 study of Erdafitinib in subjects with advanced solid tumors and FGFR gene alterations

## MYELOISCHE ERKRANKUNGEN

### AML

#### Primärtherapie

<b>AG-120 / CC- 90012 / AGILE</b>	Sascha Grabow	0341 9712621
---------------------------------------	---------------	--------------

Phase 3a Studie mit AG 120 bei Patienten mit akuter myeloischer Leukämie (AML) mit einer IDH1 Mutation

**PALOMA** Sascha Grabow 0341 9712621

Primary comparison of liposomal Anthracycline based treatment versus conventional care strategies before allogenic stem cell transplantation in patients with higher risk MDS and oligoblastic AML – the PALOMA study

**ASTX727-02** Nicole Thorn 0341 9712658

A phase 3, randomized, open-label, crossover study of ASTX727 (Cedazuridine and Decitabine fixed-dose combination) versus IV Decitabine in subjects with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML)

**DaunoDouble** Sascha Grabow 0341 9712621

Randomized comparison between two dose levels of Daunorubicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia ≤ 65 years

### Primärtherapie – Early Clinical Trials Unit Leipzig

**74494550**

**AML1003** Karolin Hubert 0341 9720363  
**ELEVATE**

An open-label, multicenter, phase 1b study of JNJ-74494550 (Cusatuzumab; Anti-CD70 monoclonal antibody) in combination with background therapy for the treatment of subjects with acute myeloid leukemia

**IMGN632-0802** Karolin Hubert 0341 9720363

Phase 1b/2 study of IMGN632 monotherapy and in combination with Venetoclax and/or Azacytidine in CD123-Positive AML patients (relapsed and front-line)

### Sekundärtherapie

**M19-708** Sascha Grabow 0341 9712621

Randomized, open-label, phase III study of Venetoclax and Azacytidine versus standard of care as maintenance therapy for patients with acute myeloid leukemia in first remission after conventional chemotherapy



## Rezidiv, refraktär

### AML003 / ARMADA 2000

Nicole Thorn

0341 9712658

Phase III multicenter open-label randomized trial to evaluate efficacy and safety of CPI-613 in combination with high dose Cytarabine and Mitoxantrone (CHAM) compared to high dose Cytarabine and Mitoxantrone (HAM) in older patients ( $\geq 60$  years) with relapsed/refractory acute myeloid leukemia (AML)

### Mautitus

Nicole Thorn

0341 9712658

Midostaurin in MRD positive acute myeloid leukemia after allogeneic stem cell transplantation

### Q-HAM

Nicole Thorn

0341 9712658

Quizartinib and high-dose Ara-C plus Mitoxantrone in relapsed/refractory AML with FLT3-ITD

### SHAPE

Sascha Grabow

0341 9712621

Treatment of MDS/AML patients with an impending hematological relapse with Azacitidine alone or in combination with Pevonedistat - a randomized phase 2 trial

### TUD- PEMAZA-068

Sascha Grabow

0341 9712621

MRD-guided treatment with Pembrolizumab and Azacitidine in NPM1 mut AML patients with an imminent hematological relapse

### ETAL3-ASAP

Katrin Stolle

0341 9713134

Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML

## Rezidiv, refraktär – Early Clinical Trials Unit Leipzig

### CA-4948-102

Karolin Hubert

0341 9720363

A phase 1, open label dose escalation trial evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered CA-4948 in patients with acute myelogenous leukemia or myelodysplastic syndrome

**67571244**  
**AML1001**

Karolin Hubert

0341 9720363

A phase 1, first-in-human, dose escalation study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in subjects with relapsed or refractory AML or MDS

**CD-TCR-001**

Karolin Hubert

0341 9720363

A phase I/II, open-label, non-randomized, multicentre, dose-escalation clinical trial with control group to evaluate the safety, feasibility and preliminary efficacy of PRAME TCR modified T cells, MDG1011, in subjects with high risk myeloid and lymphoid neoplasms

**DART - Studie**

Karolin Hubert

0341 9720363

A phase 1/2, first-in-human, dose escalation study of MGD006, a CD123 x CD3 dual affinity re-targeting (DART) bi-specific antibody-based molecule, in patients with relapsed or refractory acute myeloid leukemia or intermediate-2/high risk myelodysplastic syndrome

**ADVANCE II**  
**DCOne-002**

Karolin Hubert

0341 9720363

An international, multicenter, open-label study to evaluate the efficacy and safety of two different vaccination regimens of immunotherapy with allogenic dendritic cells, DCP-001, in patients with acute myeloid leukaemia that are in remission with persistent MRD

**IMGN632-0802**

Karolin Hubert

0341 9720363

Phase 1b/2 study of IMGN632 monotherapy and in combination with Venetoclax and/or Azacytidine in CD123-positive AML patients (relapsed and front-line)

## APL

### Primärtherapie

**APOLLO**

Dr. rer. nat.  
Andrea Bendig

0341 9713061

Eine randomisierte Phase-III-Studie zum Vergleich von Arsenitrioxid (ATO) in Verbindung mit ATRA und Idarubicin versus ATRA in Kombination mit einer Anthracyclin-basierten Chemotherapie (AIDA) bei Patienten mit neu diagnostizierter, akuter Promyelozytenleukämie mit Hochrisikomerkmale

## MDS

### Primärtherapie

**FGCL-4592-082** Karolin Hubert 0341 9720363

A phase 3 randomized double-blind placebo-controlled study investigating the efficacy and safety of Roxadustat (FG-4592) for treatment of anemia in patients with lower risk myelodysplastic syndrome (MDS) with low red blood cell (RBC) transfusion burden (LTB)

**COMMANDS** Karolin Hubert 0341 9720363

A phase 3, open-label, randomized study to compare the efficacy and safety of Luspatercept (ace-536) versus Epoetin alfa for the treatment of anemia due to ipss-r very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naïve subjects who require red blood cell transfusions

**ACE-536-LTFU-001** Katja Hammann 0341 9713131

A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who are participated in other Luspatercept (ACE-536) clinical trails

**M15-954 VERONA** Sascha Grabow 0341 9712621

A randomized, double-blind, phase 3 study evaluating the safety and efficacy of Venetoclax in combination with Azacitidine in patients newly diagnosed with higher-risk myelodysplastic syndrome (higher-risk MDS)

### Primärtherapie – Early Clinical Trials Unit Leipzig

**SLN124-002** Karolin Hubert 0341 9720363

A randomised, single-blind, placebo-controlled, phase 1, single-ascending and multiple-dose study in adult subjects with alpha/beta-thalassaemia and very low- and low-risk myelodysplastic syndrome to investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic response of SLN124

### Rezidiv, refraktär

**IDEAL** Sascha Grabow 0341 9712621

A single-arm phase II multicenter study of IDH2 (AG 221) inhibitor in patients with IDH2 mutated myelodysplastic syndrome – IDEAL

**63935937**  
**MDS3001**

Katja Hammann

0341 9713131

A study to evaluate lmetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA) treatment

**IDH2 Post Allo**

Katrin Stolle

0341 9713134

Prospective, open-label, non-randomized with 2 single noncomparative arms, multicenter phase-II trial– Enasidenib as consolidation or salvage therapy for patients with IDH2 Mutation with Relapse of AML, MDS, and CMML after allogeneic SCT

**SHAPE**

Sascha Grabow

0341 9712621

Treatment of MDS/AML patients with an impending Hematological relapse with Azacitidine alone or in combination with Pevonedistat - a randomized phase 2 trial

**PALOMA**

Sascha Grabow

0341 9712621

Primary comparison of liposomal Anthracycline based treatment versus conventional care strategies before allogenic stem cell transplantation in patients with higher risk MDS and oligoblastic AML – the PALOMA study

**BoHemE**

Sascha Grabow

0341 9712621

A prospective longitudinal cohort study to investigate the interactions of bone and hematopoiesis in the elderly

**Rezidiv, refraktär –  
Early Clinical Trials Unit Leipzig**

**CA-4948-102**

Karolin Hubert

0341 9720363

A phase 1, open label dose escalation trial evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered CA-4948 in patients with acute myelogenous leukemia or myelodysplastic syndrome

**DART - Studie**

Karolin Hubert

0341 9720363

A phase 1/2, first-in-human, dose escalation study of MGD006, a CD123 x CD3 dual affinity re-targeting (DART) bi-specific antibody-based molecule, in patients with relapsed or refractory acute myeloid leukemia or intermediate-2/high risk myelodysplastic syndrome

**67571244**  
**AML1001**

Karolin Hubert

0341 9720363

A phase 1, first-in-human, dose escalation study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in subjects with relapsed or refractory AML or MDS

**64619178**  
**EDI1001**

Karolin Hubert

0341 9720363

A phase 1, first-in-human, open-label study of the safety, pharmacokinetics, and pharmacodynamics of JNJ-64619178, an inhibitor of protein arginine methyltransferase 5 (PRMT5) in subjects with advanced cancers

**CD-TCR-001**

Karolin Hubert

0341 9720363

A phase I/II, open-label, non-randomized, multicentre, dose-escalation clinical trial with control group to evaluate the safety, feasibility and preliminary efficacy of PRAME TCR modified T cells, MDG1011, in subjects with high risk myeloid and lymphoid neoplasms

**SLN124-002**

Karolin Hubert

0341 9720363

A randomised, single-blind, placebo-controlled, phase 1, single-ascending and multiple-dose study in adult subjects with alpha/beta-thalassaemia and very low- and low-risk myelodysplastic syndrome to investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic response of SLN124

## MPN

### Sekundärtherapie

**SRA-MMB-301**

Dr. rer. nat.  
Andrea Bendig

0341 9713061

A randomized, open-label, phase 3 study to evaluate the activity of Momelotinib (MMB) or Best Available Therapy (BAT) in transfusion dependent subjects with primary myelofibrosis (PMF), post-polycythemia vera (PV) myelofibrosis, or post-essential thrombocythemia (ET) myelofibrosis who were previously treated with JAK inhibitor therapy

## Sekundärtherapie – Early Clinical Trials Unit Leipzig

**MANIFEST** Karolin Hubert 0341 9720363

A phase 1/2 study of CPI-0610, a small molecule inhibitor of BET Proteins: phase 1 (dose escalation of CPI-0610 in patients with hematological malignancies) and phase 2 (dose expansion of CPI0610 with and without Ruxolitinib in patients with myelofibrosis)

## CML

### Primärtherapie

**FASCINATION** Dr. rer. nat.  
Andrea Bendig 0341 9713061

Frontline Asciminib combination in chronic phase CML

### Rezidiv, refraktär

**ENDURE /  
CML-IX** Dr. rer. nat.  
Andrea Bendig 0341 9713061

Efficacy and safety of pegylated proline Interferon alpha 2b (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitor therapy - a randomized phase II, multicenter trial with post-study follow-up

**DasaHIT trial** Dr. rer. nat.  
Andrea Bendig 0341 9713061

DasaHIT trial, (Dasatinib Holiday for Improved Tolerability) Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naive disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line)

**PONDEROSA** Dr. rer. nat.  
Andrea Bendig 0341 9713061

Observational study on CML patients in any phase treated with Ponatinib (IclusigR) at any dose

## MULTIPLES MYELOM

### Primärtherapie

**AGMT\_MM-2** Jenny Dietrich 0341 9720364

A randomized Phase II, 2-armed study in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) comparing Carfilzomib + Thalidomide + dexamethasone (KTd) versus Carfilzomib + Lenalidomide + dexamethasone (KRd) induction therapy with respect to response rates and investigating a Carfilzomib (K) monotherapy maintenance strategy

**AGMT\_MM-3 DEFENCE** Jenny Dietrich 0341 9720364

A randomized Phase II, 2-armed study in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) comparing Carfilzomib + Thalidomide + dexamethasone (KTd) versus Carfilzomib + Lenalidomide + dexamethasone (KRd) induction therapy with respect to response rates and investigating a Carfilzomib (K) monotherapy maintenance strategy

**DSMM\_XVII** Jenny Dietrich 0341 9720364

Elotuzumab (E) in combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd ) versus KRd prior to and following autologous stem cell transplant in newly diagnosed multiple myeloma and subsequent maintenance with Elotuzumab and Lenalidomide versus single-agent Lenalidomide

### Rezidiv, refraktär

**68284528 MMY3002 Cartitude4** Jenny Dietrich 0341 9720364

A phase 3 randomized study comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) therapy directed against BCMA vs Carfilzomib and Dexamethasone (Kd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with relapsed and Lenalidomide-refractory multiple myeloma

**DREAMM 8** Jenny Dietrich 0341 9720364

A phase III, multicenter, open-label, randomized study to evaluate the efficacy and safety of Belantamab Mafodotin in combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in participants with relapsed/refractory multiple myelom

## Rezidiv, refraktär – Early Clinical Trials Unit Leipzig

R5458-  
ONC-1826

Karolin Hubert

0341 9720363

A phase I/II study that will evaluate the safety and efficacy of an exciting new BiTE compound REGN5458 (anti-BCMA x anti-CD3) as treatment in adult patients with relapsed or refractory multiple myeloma

64007957  
MMY1001

Karolin Hubert

0341 9720363

A phase 1/2, first-in-human, open-label, dose escalation study of Teclistamab, a humanized BCMA x CD3 bispecific antibody, in subjects with relapsed or refractory multiple myeloma

## LYMPHATISCHE ERKRANKUNGEN

### Primärtherapie

COPA-R-CHOP,  
UKM18\_0021

Kitty Leuschel

0341 9713133

A prospective multicenter phase 2 study of the combination of the phosphatidylinositol-3-kinase inhibitor copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)

### Rezidiv, refraktär

MOR208C204 -  
B-MIND

Kitty Leuschel

0341 9713133

A phase II/III, randomized, multicentre study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem-cell transplantation (ASCT) - B-MIND

AFM13-202,  
REDIRECT  
107652

Kitty Leuschel

0341 9713133

A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive Peripheral T-Cell Lymphoma or transformed mycosis fungoides (REDIRECT)



**R1979-  
ONC-1625**

Katja Hammann

0341 9713131

An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory B-cell non-hodgkin lymphoma

**Rezidiv, refraktär –  
Early Clinical Trials Unit Leipzig**

**MK4280-003**

Karolin Hubert

0341 9720363

A phase 1b clinical study to evaluate safety and efficacy of a combination of MK-4280 and Pembrolizumab (MK-3475) in participants with hematologic malignancies

**CC-220-  
NHL-001**

Karolin Hubert

0341 9720363

A phase 1, multicenter, open-label study to assess safety, pharmacokinetics, and preliminary efficacy of Iberdomide (CC-220), alone and in combination with anti-CD20 in subjects with relapsed or refractory lymphomas

**ALL**

**Primärtherapie**

**GMALL  
08/2013**

Kitty Leuschel

0341 9713133

Multizentrische randomisierte Studie zur Risiko- und subgruppenadaptierten Therapieoptimierung bei Erwachsenen mit ALL oder lymphoblastischen Lymphomen (Phase IV-Studie mit einem Phase III-Teil zur Evaluation der Sicherheit und Wirksamkeit von Nelarabin bei T-ALL)

**EWALL-BOLD**

Kitty Leuschel

0341 9713133

Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Blinatumomab

**Rezidiv, refraktär**

**GMALL-  
MOLACT1-  
BLINA**

Kitty Leuschel

0341 9713133

A multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody Blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Blast Successor Trial), phase II

## Rezidiv, refraktär – Early Clinical Trials Unit Leipzig

20180257

Karolin Hubert

0341 9720363

A phase 1b open-label study to investigate the safety and pharmacokinetics of administration of subcutaneous Blinatumomab for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (R/R B-ALL)

## HODGKIN LYMPHOM

### Primärtherapie

HD21

Katja Hammann

0341 9713131

HD21- Therapieoptimierungsstudie für Patienten mit Erstdiagnose eines fortgeschrittenen klassischen Hodgkin Lymphoms: eine randomisierte Phase 3 Studie

### Rezidiv

ADCT-301-201

Katja Hammann

0341 9713131

A phase 2, open-label, single-arm study to evaluate the efficacy and safety of Camidanlumab Tesirine (ADCT-301) in patients with relapsed or refractory hodgkin lymphoma

## Rezidiv – Early Clinical Trials Unit Leipzig

MK4280-003

Karolin Hubert

0341 9720363

A phase 1b clinical study to evaluate safety and efficacy of a combination of MK-4280 and Pembrolizumab (MK-3475) in participants with hematologic malignancies

## STAMMZELLTRANSPLANTATION

MOZOBL08363/  
OPTIMOB

Katja Hammann

0341 9713131

Eine deutschlandweite systematische Untersuchung der Mobilisierung und Sammlung von hämatopoetischen Stammzellen bei schlecht mobilisierbaren Patienten vor autologer Stammzelltransplantation

**JZP-381 15-007  
(VOD)**

Kitty Leuschel

0341 9713133

A phase 3, randomized, adaptive study comparing the efficacy and safety of Defibrotide vs. best supportive care in the prevention of hepatic veno-occlusive disease in adult and pediatric patients undergoing hematopoietic stem cell transplant

### Graft versus Host Disease

**INCB 39110-  
309 /  
GRAVITAS**

Katrin Stolle

0341 9713134

A phase 3 study of Itacitinibor placebo in combination with corticosteroids as initial treatment for chronic graft versus host disease (GRAVITAS 309)

**MC-MSC.1  
IDUNN**

Katrin Stolle

0341 9713134

A randomised, open-label, multicentre, phase 3 trial of first-line treatment with mesenchymal stromal cells MC0518 versus best available therapy in adult and adolescent subjects with steroid-refractory acute graft-versus host disease after allogeneic haematopoietic stem cell transplantation / IDUNN

### CMV

**SHP620-302  
AURORA**

Kitty Leuschel

0341 9713133

A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of Maribavir compared to Valganciclovir for the treatment of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant recipients

### MCL

**TRIANGLE**

Katrin Stolle

0341 9713134

Autologous transplantation after a Rituximab/Ibrutinib/Ara-C containing induction in generalized mantle-cell lymphoma - a randomized European MCL Network Trial

## ZELLTHERAPIE

### Lymphom

**M-2016-312,  
CART20.1** Kitty Leuschel 0341 9713133

A phase I/II safety, dose finding and feasibility trial of MB-CART20.1 in MB patients with relapsed or resistant CD20 positive B-NHL

### Multiples Myelom

**64007957  
MMY1001** Karolin Hubert 0341 9720363

A phase 1/2, first-in-human, open-label, dose escalation study of Teclistamab, a humanized BCMA x CD3 bispecific antibody, in subjects with relapsed or refractory multiple myeloma

**68284528  
MMY3002  
Cartitude4** Jenny Dietrich 0341 9720364

A phase 3 randomized study comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) therapy directed against BCMA vs Carfilzomib and Dexamethasone (Kd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with relapsed and Lenalidomide-refractory multiple myeloma

### Early Clinical Trials Unit Leipzig

**UC02-123-01** Karolin Hubert 0341 9720363

Multizentrische, offene Phase I Studie mit Dosissteigerungen für die Behandlung von Patienten mit CD123 positiven hämatologischen und lymphatischen Malignomen mittels gentechnisch veränderten T-Zellen, die universelle chimäre Antigen-Rezeptoren (UniCAR02-T) auf der Oberfläche tragen, und in Kombination mit einem CD123-spezifischen Zielmodul (TM123) verabreicht werden

## PSYCHOONKOLOGISCHE VERSORGUNG

**SALUT** Dr. Peter Esser 0341 9718800

Trauma- und belastungsbezogene Störungen bei hämatologischen Krebspatienten: Eine Interview-basierte Studie anhand aktualisierter diagnostischer Kriterien

**Peer2Me**Dr. Diana Richter/  
Dr. Kristina Geue0341 9715426/  
0341 9715438

Peer2Me 2.0 – Evaluation eines Peer-MentoringProgramms zur Unterstützung junger Erwachsener mit Krebs

**LUPE**Prof. Dr. phil. Anja  
Mehner-Theuerkauf

0341 9718800

Längsschnittanalyse des psychoonkologischen Unterstützungsbedarfs bei Patienten und deren Angehörigen stratifiziert nach biopsychosozialen Einflussfaktoren

**OptiScreen**Prof. Dr. phil. Anja  
Mehner-Theuerkauf

0341 9718800

Optimierte psychoonkologische Versorgung durch einen interdisziplinären Versorgungsalgorithmus – vom Screening zur Intervention

**AYA-LE  
Längsschnitt 2**

Dr. Kristina Geue

0341 9715438

Peer2Me 2.0 – Evaluation eines Peer-Mentoringprogramms zur Unterstützung junger Erwachsener mit Krebs

**AOK**Prof. Dr. phil. Anja  
Mehner-Theuerkauf

0341 9718800

Entwicklung eines Online-Coaches für Angehörige von an Krebs erkrankten Menschen

**OnkoDigitaltrial**Prof. Dr. phil. Anja  
Mehner-Theuerkauf

0341 9718800

OnkoDigitaltrial – digitale Begleitung von Patient:innen mit Krebserkrankung für eine nachhaltige Verbesserung der Lebensqualität

**QualityOfLife**Prof. Dr.  
Andreas Hinz

0341 9718820

Gesundheitsbezogene Lebensqualität in der Onkologie und Palliativmedizin: Die Beziehung zwischen Wichtigkeits- und Zufriedenheitsurteilen

**ONKO-STEP**Dr. Kristina Geue/  
Prof. Dr. phil. Anja  
Mehner-Theuerkauf0341 9715438/  
0341 9718800

Wirksamkeit der kognitiv-behavioralen Online-Schreibtherapie Onko-STEP für Krebspatienten im jungen Erwachsenenalter – eine randomisierte kontrollierte Studie

## ALL PÄDIATRIE

### Primärtherapie

**AIEOP-BFM ALL 2017** Kerstin Faulhaber 0341 9726173

Internationales kooperatives Behandlungsprotokoll Kinder und Jugendliche mit Akuter lymphatischer Leukämie

**EsPhALL2017/ COGAALL1631** Kerstin Faulhaber 0341 9726173

Internationale Therapiestudie zur Behandlung von Kindern und Jugendlichen mit Philadelphia-positiver Akuter Lymphoblastischer Leukämie

### Rezidiv

**IntReALL HR 2010** Kerstin Faulhaber 0341 9726173

International study for treatment of high risk childhood relapsed ALL 2010

**ALL-REZ BFM Register** Kerstin Faulhaber 0341 9726173

Beobachtungsstudie und Biobank für Rezidive einer akuten lymphatischen Leukämie im Kindes-und Jugendalter

## AML PÄDIATRIE

### Register

**AML-BFM 2017** Kerstin Faulhaber 0341 9726173

Register zur Erfassung der myeloischen Leukämien bei Kindern und Jugendlichen

## CML PÄDIATRIE

### Primärtherapie

**CML-paed-II-Register** Kerstin Faulhaber 0341 9726173

Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with philadelphia chromosome-positive chronic myeloid leukemia (CML)

## MDS PÄDIATRIE

### Primärtherapie

**EWOG-  
MDS-2006**

Kerstin Faulhaber

0341 9726173

Prospective non randomized multicenter study for epidemiology and characterization of myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) in childhood

## LYMPHOM PÄDIATRIE

### Primärtherapie

**B-NHL 2013**

Kerstin Faulhaber

0341 9726173

Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents

**LBL 2018**

Kerstin Faulhaber

0341 9726173

International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma

## NEUROBLASTOME PÄDIATRIE

### Primärtherapie

**Neuroblastom-  
Register**

Kerstin Faulhaber

0341 9726173

Erfassung von Säuglingen, Kindern und Jugendlichen und jungen Erwachsenen mit neu diagnostizierten und/oder Rückfall eines neuroblastischen Tumors

### Rezidiv

**Metro-NB 2012**

Kerstin Faulhaber

0341 9726173

Metronomische Behandlung von Kindern und Jugendlichen mit rezidiviertem oder progredientem Neuroblastom

## NEPHROBLASTOME PÄDIATRIE

### Primärtherapie

**SIOP 2001/  
GPOH**

Kerstin Faulhaber

0341 9726173

Chemotherapy before and after surgery in treating children with Wilm's Tumor

## HEPATOBLASTOME PÄDIATRIE

**PHITT Studie** Kerstin Faulhaber 0341 9726173

Paediatric hepatic international tumor trial

## HIRNTUMORE PÄDIATRIE

### Primärtherapie

**CPT-SIOP-2009** Kerstin Faulhaber 0341 9726173

Intercontinental multidisciplinary registry and treatment optimization study for patients with choroid plexus tumors

**Kraniopharyngeom Register 2019** Kerstin Faulhaber 0341 9726173

Multicenter registry for patients with childhood-onset craniopharyngioma, xanthogranuloma, cysts of Rathke's pouch, meningioma, pituitary adenoma, arachnoid cysts

**SIOP Ependymoma II** Kerstin Faulhaber 0341 9726173

An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma

**I-HIT-Med** Kerstin Faulhaber 0341 9726173

For children, adolescents, and adults with medulloblastoma, ependymoma, pineoblastoma, CNS-primitive neuroectodermal tumours

**EU-RHAB** Kerstin Faulhaber 0341 9726173

A multinational registry for rhabdoid tumors of any anatomical site

**SIOP PNET 5 MB-LR und -SR** Kerstin Faulhaber 0341 9726173

Internationale, prospektive, randomisierte (SR) Phase II/III-Studie für Kinder älter als 3-5 Jahren und jünger als 16.0 Jahre (LR) bzw. geringer als 22.0 Jahre (SR) mit einem klinischen Standardrisiko-Medulloblastom und niedrigem (LR) bzw. durchschnittlichem (SR) biologischen Risikoprofil



**HIT-HGG-2013** Kerstin Faulhaber 0341 9726173

International cooperative phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 years

**HIT-LOGGIC Register** Kerstin Faulhaber 0341 9726173

Prospektives multizentrisches Register für Kinder- und Jugendliche mit einem niedrig-gradigen Gliom

## Rezidiv

**HIT-REZ Register** Kerstin Faulhaber 0341 9726173

Multinationales multizentrisches Register für Kinder, Jugendliche und junge Erwachsene mit therapierefraktären oder rezidivierten Medulloblastomen, Pineoblastomen, primitiv neuroektodermalen Tumoren des ZNS (ZNS-PNET's) und Ependymomen

## SARKOME PÄDIATRIE

### Primärtherapie

**CWS 2007-HR** Kerstin Faulhaber 0341 9726173

Trial for localised high-risk rhabdomyosarcoma and rhabdomyosarcoma-like soft tissue sarcoma

**rEECur** Kerstin Faulhaber 0341 9726173

International randomised controlled trial for the treatment of recurrent and primary refractory ewing sarcoma

**CWS-Register SoTiSaR** Kerstin Faulhaber 0341 9726173

A registry for soft tissue sarcoma and other soft tissue tumours in children, adolescents, and young adults

**COSS-Register** Kerstin Faulhaber 0341 9726173

Register der Cooperativen Osteosarkomstudiengruppe COSS

## KEIMZELLTUMORE

**Makei V** Kerstin Faulhaber 0341 9726173

Multizentrische prospektive Studie zu einem randomisierten Vergleich von Carboplatin mit Cisplatin bei extrakraniellen malignen Keimzelltumoren

## SELTENE TUMORE PÄDIATRIE

**GPOH-MET** Kerstin Faulhaber 0341 9726173

Register zur Erfassung maligner endokriner Tumoren im Kindes- und Jugendalter

**STEP** Kerstin Faulhaber 0341 9726173

Seltene Tumoren, die nicht in prospektive Behandlungsstudien oder Register der GPOH eingeschlossen werden

**INFORM** Kerstin Faulhaber 0341 9726173

Individualized therapy for relapsed malignancies in childhood

**Lebertumor-register** Kerstin Faulhaber 0341 9726173

Register für Lebertumoren bei Kindern und Jugendlichen

**NPC-2016** Kerstin Faulhaber 0341 9726173

A multicenter registry of nasopharyngeal cancer in children, adolescents and young adults

**Retinoblastom-register** Kerstin Faulhaber 0341 9726173

Register für die Retinoblastomerkrankung in Deutschland und Österreich



## NOTIZEN



## NOTIZEN



## ANSPRECHPARTNER/KONTAKT

### **Dr. Ivonne Haffner**

Universitätsklinikum Leipzig

Leitung klinische Forschung

Liebigstraße 22, Haus 7; 04103 Leipzig

Tel.: 0341 9712570

E-Mail: [studienzentrale.uccl@medizin.uni-leipzig.de](mailto:studienzentrale.uccl@medizin.uni-leipzig.de)

## STUDIEN DURCHFÜHRENDE EINHEITEN AM UNIVERSITÄTSKLINIKUM LEIPZIG

Universitäres Krebszentrum Leipzig (UCCL)

Direktor Prof. Dr. Florian Lordick

Klinik und Poliklinik für Strahlentherapie

Direktor Prof. Dr. Rolf-Dieter Kortmann

Klinik und Poliklinik für Neurochirurgie

Direktor Prof. Dr. Jürgen Meixensberger

Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie

Direktor Prof. Dr. Jan C. Simon

Medizinische Klinik und Poliklinik für Onkologie,  
Gastroenterologie, Hepatologie, Pneumologie und  
Infektiologie (II)

komm. Direktor Prof. Dr. Thomas Berg

Klinik und Poliklinik für Urologie

Direktor Prof. Dr. Jens-Uwe Stolzenburg

Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde

Direktor Prof. Dr. Andreas Dietz

Klinik und Poliklinik für Frauenheilkunde

Direktorin Prof. Dr. Bahriye Aktas

Klinik und Poliklinik für Viszeral-, Transplantations-,  
Thorax- und Gefäßchirurgie

Direktoren Prof. Dr. Ines Gockel (Viszeralchirurgie) und  
Prof. Dr. Daniel Seehofer (Hepatobiliäre Chirurgie)

Medizinische Klinik und Poliklinik für Hämatologie,  
Zelltherapie und Hämostaseologie (I)

Direktoren Prof. Dr. Uwe Platzbecker und  
Prof. Dr. Florian Lordick

Abteilung für Pneumologie

Leiter Prof. Hubert Wirtz

Abteilung Medizinische Psychologie und Medizinische  
Soziologie

Leiterin Prof. Dr. Anja Mehnert-Theuerkauf

Abteilung für Pädiatrische Onkologie, Hämatologie und  
Hämostaseologie

Leiter Prof. Dr. Holger Christiansen